Short answer
Twist Bioscience Corp (TWST) filed its fiscal 2025 10-K annual report with the SEC on Nov 17, 2025. It reported revenue of $377M (+20.3% year over year) and net income of −$78M.
- Top risk flagged: Regulatory risk: dependency on ISO 27001:2022 cybersecurity certification for information security management systems impacting operations and data protection
FY2025 key financial metrics · XBRL
- Revenue
- $377M
- +20.3% YoY
- Net income
- −$78M
- +62.8% YoY
- Operating margin
- -36.2%
- +34.4 pp YoY
- EPS (diluted)
- −$1.30
- +63.9% YoY
- ROE
- -16.4%
- +27.7 pp YoY
- Operating cash flow
- −$48M
- +25.7% YoY
Source: XBRL data from the Twist Bioscience Corp (TWST) FY2025 10-K on SEC EDGAR. USD.
Twist Bioscience Corp FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Synthetic DNA production and related biotechnological research and manufacturing
- Strategic real estate expansion: Lease amendment adds 33,000 sq. ft. for R&D, manufacturing, and administration in South San Francisco
- Lease extended to June 30, 2036 with $119.2M total rent obligations including 3% annual rent escalations
- $24.4M tenant improvement allowance from landlord to support facility upgrades
- Option to expand by another 33,000 sq. ft. by December 31, 2026 on fourth floor
Management Discussion & Analysis
- Revenue $376.6M, up 20% YoY from $313.0M, driven by NGS tools +$39.0M and synthetic genes +$20.9M
- Gross margin 50.7% vs 42.6%, up 8.1% due to revenue growth and flat fixed manufacturing costs
- Best segment: NGS tools $208.1M (55% of revenue), worst: DNA libraries $11.2M (3% of revenue)
- Net cash used in operating activities $47.6M vs $64.1M; capital expenditures $28.0M; financing cash inflow $28.5M including $15.0M from royalty sale
- Management expects current cash, investments and operations to fund >12 months but may raise financing if needed; significant lease expansion signed through 2036
Risk Factors
- Regulatory risk: dependency on ISO 27001:2022 cybersecurity certification for information security management systems impacting operations and data protection
- Geopolitical/macroeconomic risk: exposure to cyberattacks by nation-state actors risking technology theft and operational disruption
- Operational vulnerability: reliance on single-source supplier for critical DNA synthesis component risking production delays
- Competitive risk: rivalry with Thermo Fisher Scientific, Illumina, and others who may develop silicon chip synthetic DNA technologies threatening market position
- Financial risk: accumulated deficit $1,319.6M and net losses $204.6M-$208.7M in prior years raising sustainability concerns
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.